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Abstract 
Agathisflavone is a bioactive compound in Anacardium occidentale. In this study we 
investigated inhibition neuroinflammation in BV2 microglia by agathisflavone. 
Neuroprotective activity of the compound was investigated in differentiated SH-SY5Y 
cells. Experiments in LPS-activated BV2 microglia showed that pre-treatment with 
agathisflavone (5-20 µM) produced significant reduction in the release of TNFα, IL-6, 
IL-1β, NO and PGE2 from the cells. Immunoblotting experiments also revealed that 
agathisflavone reduced levels of iNOS and COX-2 protein. Further studies revealed 
that agathisflavone reduced neuroinflammation by targeting critical steps in NF-κB 
signalling in BV2 microglia. Treatment of SH-SY5Y cells with conditioned medium 
from LPS-activated BV2 microglia produced a significant reduction in neuronal 
viability. However, conditioned medium from BV2 cells which were stimulated with 
LPS in the presence of agathisflavone did not induce neurotoxicity. Agathisflavone 
also produced neuroprotection in APPSwe plasmid-transfected SH-SY5Y neurons. 
The compound further attenuated LPS- and APPSwe plasmid-induced reduction in 
SIRT1 in BV2 microglia and SH-SY5Y, respectively. In the presence of EX527, 
agathisflavone lost its anti-inflammatory and neuroprotective activities. Our results 
suggest that agathisflavone inhibits neuroinflammation in BV2 microglia by targeting 
NF-κB signalling pathway. The compound also reduces neurotoxicity through 
mechanisms that are possibly linked to SIRT1 in the microglia and neurons. 
 
Keywords 
Agathisflavone, Anacardium occidentale, Neuroprotection, NF-κB, SIRT1
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Introduction 
Neuroinflammation is now known to be strongly linked to the progression of 
neurodegenerative disorders such as Alzheimer's disease (AD), Parkinson's disease 
(PD), and amyotrophic lateral sclerosis (ALS) (Hou et al., 2014). Neuroinflammation 
has been particularly linked to the pathogenesis of AD. An important feature of 
neuroinflammation is excessive microglia activation and the production of large 
amounts of pro-inflammatory cytokines and other inflammatory mediators such as 
tumour necrosis factor-α (TNFα), interleukin-1β (IL-1β), nitric oxide, and reactive 
oxygen species (Ishihara et al., 2015). Consequently, neuroinflammation remains a 
critical target for novel therapeutics for AD and other neurodegenerative conditions. 
Nuclear Factor-kappa B (NF-κB) is a transcription factor which regulates the 
production of pro-inflammatory mediators during microglia activation. Inactive NF-κB 
is normally complexed to the inhibitory protein IκB in the cytoplasm. However, 
following activation of the microglia by inflammatory stimuli such as 
lipopolysaccharide (LPS) or the pro-inflammatory cytokines, IκB becomes 
phosphorylated and degraded. This results in nuclear translocation of NF-κB (Verma 
et al., 1995; Ghosh et al., 1998; Cao et al., 2011), with subsequent activation 
resulting in pro-inflammatory gene expression (Baldwin Jr, 1996). 
Natural products are an important source of new treatments for neurodegenerative 
disorders like AD. For example, natural polyphenols modulate the functions of a 
number of therapeutic targets involved in the disease. Polyphenols are known to be 
effective in investigations into neurodegeneration due to their antioxidant, anti-
inflammatory, and antiamyloidogenic effects (Pérez-Hernández et al., 2016). 
Anacardium occidentale is a medicinal plant that is commonly employed in Africa for 
the treatment of arthritis, fever, aches, pains, and as anti-inflammatory (Olajide et al., 
2004). Previously, extracts from the plant have been shown to produce anti-
inflammatory effect in vivo (Olajide et al., 2004; Mota et al., 1985; Pawar et al., 2000; 
Vilar et al., 2016). Recently, we showed that the stem bark extract of the plant 
inhibited NF-κB-mediated neuroinflammation in LPS-activated BV2 microglia (Olajide 
et al., 2013). Agathisflavone is a biflavonoid found in many plants, including 
Anacardium occidentale (Ajileye et al., 2015). This compound has been reported to 
produce hepatoprotective effect (Anand et al., 1992), cytotoxicity to cancer cells 
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(Konan et al., 2012; Ndongo et al., 2015; Taiwo et al., 2017) and antioxidant 
activities (Ajileye et al., 2015). In spite of the pharmacological potentials of 
agathisflavone, nothing is known about its ability to inhibit neuroinflammation. In this 
study, we explored inhibition of NF-κB-mediated neuroinflammation by 
agathisflavone isolated from the leaves of A. occidentale. We also report significant 
inhibition of neuroinflammation- and amyloid beta-induced neurotoxicity by the 
compound. 
Materials and methods 
Plant material 
Leaves of Anacardium occidentale were collected in Ile-Ife, Nigeria and 
authenticated in the Department of Botany, Obafemi Awolowo University, Ile-Ife, 
Nigeria. A voucher specimen (IFE Herbarium: 16834) was deposited in the 
Herbarium. The leaves were air dried at room temperature and ground to a powder. 
Extraction, isolation and characterization of agathisflavone 
Activity directed isolation procedure for agathisflavone from the ethyl acetate soluble 
fraction of the crude extract of 80% methanol of A. occidentale leaves and 
subsequent characterisation of the compound using spectroscopic methods were as 
previously reported (Ajileye et al., 2015). 
Cell culture 
BV2 mouse microglia cell line ICLC ATL03001 (Interlab Cell Line Collection, Banca 
Bilogica e Cell Factory, Italy) were cultured in RPMI 1640 medium with 10% foetal 
bovine serum (Sigma), 2 mM L-glutamine (Sigma), 100 U/mL penicillin and 100 
mg/mL streptomycin (Sigma) in a 5% CO2 incubator. Cells were treated with LPS 
(100 ng/mL; from Salmonella typhimurium; Innaxon, UK). 
SH-SY5Y human neuroblastoma cells (ECACC 94030304) were cultured in Ham's 
F12: EMEM (EBSS) with15% FBS, 2mM Glutamine and 1% non-essential amino 
acids (NEAA) in a 5% CO2 incubator. SH-SY5Y were differentiated with retinoic acid 
(10 µM). 
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BV2 Cell viability experiment 
The MTT assay was performed as described previously (Olajide et al., 2013), and 
was used to determine the viability of BV2 microglia which were pre-treated with 
agathisflavone (5-20 µM) 30 min prior to stimulation with LPS (100 ng/mL) for 24 h. 
After stimulation, 200 µL MTT solution (5 mg/mL) was added to cells followed by 
incubation at 37°C for 4 h. Then, 200 µL of medium was removed from each well, 
and 150 µL of DMSO solution added to wells. The plate was shaken briefly and 
absorbance was read at 540 nm with a plate reader (Infinite F50, Tecan). 
Production of pro-inflammatory cytokines, nitrite and PGE2 
BV2 cells were treated with agathisflavone (5-20 µM) for 30 min and then stimulated 
with LPS for 24 h. Culture supernatants were collected and centrifuged. 
Concentrations of TNFα and IL-6 were measured with commercially available ELISA 
kits (BioLegend, UK), followed by measurements in a plate reader at a wavelength of 
450 nm. Levels of nitrite in culture supernatants were measured using commercially 
available Griess assay kit (Promega) according to manufacturer’s instructions. 
Absorbance was measured at 540 nm in a microplate reader. Levels of PGE2 in 
supernatants were measured using commercially available enzyme immunoassay kit 
(Arbor Assays, Ann Arbor, Michigan, USA) according to manufacturer’s instructions. 
Absorbance was measured at 450 nm in a microplate reader. 
Detection of cellular reactive oxygen species (ROS) 
The effect of LPS on intracellular ROS levels in BV2 microglia was carried out using 
the fluorescent 2’, 7’-dichlorofluorescin diacetate (DCFDA)-cellular ROS detection 
assay kit (Abcam). DCFDA (10 µM) was added to cultured BV2 microglia and 
incubated for 30 min at 37°C. Following removal of excess DCFDA, cells were 
washed and then treated with agathisflavone (5-20 µM) for 30 min and then 
stimulated with LPS (100 ng/mL) for a further 4 h at 37°C. Intracellular generation of 
ROS was detected by in a microplate reader with a fluorescence excitation 
wavelength of 485 nm and emission wavelength of 535 nm. 
Western blotting 
Western blotting was carried out as described elsewhere (Olajide et al., 2013). The 
following primary antibodies were used: anti-rabbit iNOS (1:500, Santa Cruz), rabbit 
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anti-COX-2 (1:500; Santa Cruz), rabbit phospho-IκBα (1:250; Santa Cruz), rabbit 
anti-total IκB (1:250; Santa Cruz) and rabbit anti-actin (1:1000; Sigma). Proteins 
were detected with horseradish peroxidase (HRP)-coupled secondary antibodies 
using enhanced chemiluminescence (ECL) western blotting substrate (Licor). All 
Western blot experiments were carried out at least three times. 
ELISA for phospho-p65 
Cultured BV2 microglia were treated with agathisflavone (5-20 µM) for 30 min. This 
was followed by stimulation with LPS (100 ng/mL) for a further 15 min. Following 
stimulation, cell lysates were analysed for levels of phospho-p65 protein using an 
ELISA kit (eBioscience, UK), according to the manufacturer’s instructions. 
Immunofluorescence for NF-κB 
This was carried out using a procedure described elsewhere (Velagapudi et al., 
2017). BV2 cells were pre-treated with agathisflavone (5-20 µM) for 30 min followed 
by stimulation with LPS (100 ng/mL) for 60 min. Immunofluorescence detection of 
rabbit anti-NF-κB p65 antibody (Santa Cruz; 1:100) was carried with Alexa Fluor 
488-conjugated donkey anti rabbit IgG secondary antibody (Life Technologies; 
1:500) and images obtained using EVOS® FLoid® cell imaging station. 
NF-κB reporter gene assay 
In order to determine the effect of agathisflavone on NF-κB-mediated gene 
expression, a luciferase reporter gene assay was carried out as described earlier 
(Okorji et al., 2014). HEK293 cells were transfected with a Cignal® NF-κB 
(SABiosciences) reporter, using TransIT®-LT1 transfection reagent (Mirus Bio LLC) 
and incubated for a further 16 h at 37°C in 5% CO2. Transfected HEK293 cells 
treated with agathisflavone (5-20 µM), and followed by stimulation with TNFα 
(1 ng/mL) for 6 h. NF-κB-mediated gene expression was measured with Dual-Glo 
luciferase assay kit (Promega, Southampton, UK) according to the manufacturer's 
instructions using a Polarstar Optima Plate reader. 
NF-κB DNA binding assay 
NF-κB DNA binding assay was carried out as earlier described (Okorji et al., 2016). 
DNA binding assay was carried on nuclear extracts using the TransAM NF-κB 
transcription factor EMSA kit (Activ Motif, Belgium), which employs a 96-well plate to 
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which an oligonucleotide containing the NF-κB consensus site (5’ GGGACTTTCC-3’) 
has been immobilised. Cells were treated with agathisflavone (5-20 µM) followed by 
LPS (100 ng/ml). 
Conditioned media-induced neurotoxicity 
BV2 cells were pre-treated with agathisflavone (5-20 µM) for 30 min and stimulated 
with LPS (1 µg/ml) for 48 h. Stimulation was terminated by removing supernatants 
(conditioned medium) from the cells. Supernatants were centrifuged at 2500 rpm for 
5 min to remove cellular debris, and then stored at -80°C. At confluence, cultured 
SH-SY5Y neuronal cells were seeded at a density of 2 × 105 cells /ml in 24-well cell 
culture plates. Cells were allowed to settle for ~24 h in a 5% CO2 incubator at 37°C. 
Later, medium was removed from the SH-SY5Y cells and replaced with conditioned 
medium. Cells were incubated for a further 24 h in 5% CO2 at 37°C. Neuronal 
viability was determined using MTT cell viability assay.  
APPSwe-transfection of SH-SY5Y neuronal Cells 
pCAX APP Swe/Ind (Addgene plasmid # 30145) and pCAX APP 695 (Addgene 
plasmid # 30137) were gifts from Dennis Selkoe & Tracy Young-Pearse 
(Young-Pearse et al., 2007). SH-SY5Y cells were transiently transfected with 4 µg of 
each plasmid using and 10 µl of lipofectamine 2000 (Thermo Fisher Scientific) in 
Opti-MEM according to the manufacturer’s instructions. Six hours after transfection, 
cells were treated with agathisflavone (5-20 µM). After 48 h, the degree of 
neurotoxicity was measured using MTT. 
SIRT1 ELISA 
Following exposure to conditioned medium or transfection with APPSwe plasmid, 
SH-SY5Y were assayed for SIRT1 activity using SIRT1 ELISA (Abcam).  
Statistical analyses 
Values of all experiments were represented as a mean ± SEM of at least 3 
independent experiments. Values were compared using one-way analysis of 
variance (ANOVA) followed by a post-hoc Student Newman-Keuls test. 
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Results and discussion 
Agathisflavone did not affect viability of BV2 microglia  
A cell viability assay was carried out in this study to assess whether concentrations 
of agathisflavone used in this study affected the viability of cultured BV2 microglia. 
Results of the MTT viability assay in Figure 2 show that at concentrations of 5, 10 
and 20 µM agathisflavone did not affect the viability of BV2 microglia. This 
observation suggests that any reduced signals in subsequent experiments were not 
due to a reduction in cell numbers. 
Agathisflavone suppressed the release of pro-inflammatory cytokines in LPS-
activated BV2 microglia 
Recruited microglia are known to release excessive amounts of pro-inflammatory 
cytokines. Furthermore, mutations in genes which control the release of IL-1β, IL-6 
and TNFα have been associated with increased risk of late onset AD 
(Papassotiropoulos et al., 1999; Nicoll et al., 2000; McCusker et al., 2001; Minter et 
al., 2016). In our study, stimulation of BV2 microglia resulted in a characteristic 
increase in the levels of pro-inflammatory cytokines TNFα, IL-6 and IL-1β 
(Figures 2A, B and C). However, in the presence of agathisflavone, there was a 
significant (p<0.05) and concentration-dependent reduction in the production of all 
the cytokines in LPS-activated BV2 microglia. Consequently, inhibition of pro-
inflammatory cytokine production by agathisflavone indicates that the compound 
may have a promising application in AD therapeutics. 
Agathisflavone prevented LPS-induced ROS generation in BV2 microglia 
During chronic activation of the microglia, neurotoxic ROS (H2O2, O2
−) are released 
to promote neurotoxicity (Block and Hong, 2005). Furthermore, there is evidence that 
NADPH oxidase (NOX) is activated in microglia, resulting in the formation of ROS 
which damages neighbouring neurons in AD (Shimohama et al., 2007). We therefore 
tested the effect of agathisflavone on LPS-induced ROS generation in BV2 microglia. 
In Figure 4, LPS is shown to produce a significant (p<0.001) elevation of ROS 
generated in BV2 microglia, when compared with unstimulated cells. Pre-treatment 
with agathisflavone (5-20 µM) resulted in significant (p<0.01) and concentration-
dependent reduction in ROS production by LPS. Studies have also shown that 
(NOX)-mediated increase in intracellular ROS levels in microglia amplifies 
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pro-inflammatory cytokine release and primes the microglia to be sensitive to further 
stimuli (Qin et al., 2004; Block et al., 2007; Surace and Block, 2012). These results 
therefore suggest that reduction in elevated ROS levels in neuroinflammation would 
contribute to the activity of agathisflavone in neurodegeneration. 
Agathisflavone reduced the production of nitric oxide and levels of iNOS 
protein in BV2 microglia stimulated with LPS 
Excessive nitric oxide production has been identified as one of the critical factors in 
the pathogenesis of several neurodegenerative diseases. Furthermore, excessive 
release of nitric oxide in neuroinflammation leads to the formation of reactive 
nitrogen species and subsequent neuronal cell death (Yutse et al., 2015). We were 
therefore interested in determining whether agathisflavone would attenuate iNOS-
mediated NO production in LPS-induced neuroinflammation. Expectedly, stimulation 
of BV2 microglia resulted in significant (p<0.001) increase in nitrite production, which 
was then significantly (p<0.05) reduced by agathisflavone in a concentration-
dependent manner (Figure 5A). Similarly, LPS produced a marked increase in 
protein levels of iNOS (Figure 5B). Pre-treating cells with agathisflavone (5-10 µM) 
resulted in significant (p<0.001) reduction in elevated levels of iNOS protein, 
suggesting that the compound prevented NO production through inhibition of iNOS 
protein expression in LPS-activated microglia. 
COX-2-mediated PGE2 production in LPS-activated BV2 microglia was inhibited 
by agathisflavone 
We also investigated effects of increasing concentrations of agathisflavone on PGE2 
production and COX-2 protein in LPS-stimulated BV2 microglia. Our results show 
that pre-treatment with agathisflavone prior to LPS stimulation produced marked 
reduction in PGE2 production in BV2 microglia (~3-fold reduction with 5 µM) 
(Figure 6A). Also, protein levels of COX-2 were significantly (p<0.001) increased with 
LPS stimulation, compared with control unstimulated cells. When we pre-treated the 
cells with agathisflavone (5-20 µM), there was significant (p<0.05) and 
concentration-dependent reduction in COX-2 protein expression (Figure 6B). 
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Agathisflavone targets IκB/NF-κB activation to inhibit neuroinflammation in 
BV2 microglia 
Encouraged by results showing that agathisflavone inhibited neuroinflammation in 
LPS-activated BV2 microglia, we decided to determine whether the compound acts 
through activation of IκB/NF-κB signalling. Firstly, we were interested to determine 
whether agathisflavone would produce a general effect on NF-κB-dependent gene 
expression. To achieve this we transfected HEK293 cells with a plasmid construct 
bearing a luciferase reporter gene under the control of NF-κB. Figure 7A shows that 
stimulation of transfected HEK293 cells with TNFα (1 ng/mL) resulted in significant 
(p<0.001) NF-κB-driven luciferase expression. However, on treating the cells with 
agathisflavone (5-20 µM), there was a concentration-dependent reduction in 
luciferase activity. 
We next investigated individual steps in the signalling pathway involved in the 
activation of this transcription factor. One of the early steps in the activation of NF-κB 
following LPS stimulation is the phosphorylation and degradation of IκB (the inhibitor 
of NF-κB) (Hayden and Ghosh, 2012). Using immunoblotting, we showed that 
agathisflavone (10 and 20 µM) produced significant (p<0.001) inhibition of LPS-
induced IκB phosphorylation in BV2 microglia; at a concentration of 5 µM, the 
compound did not produce an inhibitory effect. (Figure 7B). Interestingly, significant 
(p<0.05) inhibition of LPS-induced degradation of IκB was observed at all tested 
concentrations of the compound (Figure 7B). These data suggest that agathisflavone 
possibly acts to inhibit NF-κB signalling in LPS-activated microglia by preventing 
events which result in its nuclear translocation. This was confirmed with an ELISA, 
which shows a significant (p<0.01) inhibition of LPS-induced elevation of the levels of 
phosphorylated p65 subunit by agathisflavone (5-20 µM) (Figure 7C). Also, 
immunofluorescence experiments revealed that nuclear accumulation of p65 subunit 
as a result of LPS stimulation was reduced in the presence of agathisflavone 
(Figure 7D). 
Finally, we carried out a DNA binding assay to establish the effect of agathisflavone 
on DNA binding of NF-κB following stimulation with LPS. Figure 7E shows that that 
stimulation of BV2 cells with LPS (100 ng/mL) resulted in an increase in DNA binding 
of NF-κB, when compared with unstimulated control cells. When cells were treated 
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with agathisflavone (5-20 µM), there was a concentration-dependent and significant 
(p<0.001) reduction of DNA binding. These results confirm that agathisflavone acts 
on the early stages of NF-κB signalling pathway following LPS stimulation of BV2 
microglia. The results also confirm that the compound prevents neuroinflammation 
by targeting NF-κB. 
Several flavonoids have been shown to exert NF-κB inhibitory activity in 
neuroinflammation. Similar results have been reported for flavonoids such as 
tiliroside, kolaviron (a biflavonoid in Garcinia kola), genistein, luteolin and apigenin 
(Velagapudi et al., 2014; Onasanwo et al., 2016; Jang et al., 2010; Ha et al., 2008; 
Park et al., 2007). 
Agathisflavone protected SH-SY5Y cells from neuroinflammation-and amyloid-
mediated neurotoxicity 
A strong link now exists between neuroinflammation and neurodegeneration 
(Calsolaro and Edison, 2016). Based on our observation that agathisflavone inhibits 
neuroinflammation in BV2-stimulated microglia, we were encouraged to evaluate 
neuroprotective effect of the compound. Firstly, we treated BV2 microglia with 
agathisflavone (5-20 µM) prior to stimulation with a high concentration (1 µg/mL) 
LPS. The resulting conditioned medium was added to cultured SH-SY5Y to induce 
characteristic neurotoxicity. Expectedly, exposure of SH-SY5Y to conditioned 
medium from LPS-stimulated microglia resulted in marked reduction in cell viability 
(Figure 8A). On exposing the cells to conditioned media from BV2 microglia pre-
treated with agathisflavone (5-20 µM) prior to LPS, cell viability was significantly 
(p<0.05) increased in a concentration-related manner. It appears that the ability of 
agathisflavone to inhibit neuroinflammation in the microglia resulted in reduced levels 
of neurotoxic mediators in the conditioned media. Activation of the microglia is a 
critical contributor to neurotoxicity due to the production of the pro-inflammatory 
cytokines, ROS, NO and PGE2 (Gao et al., 2011). These results therefore suggest 
that neuroinflammation-mediated toxicity was attenuated by agathisflavone, resulting 
in a neuroprotective activity. 
We also tested the effect of agathisflavone on amyloid-induced neurotoxicity, by 
transfecting SH-SY5Y with APPSwe plasmid and then treating cells with graded 
concentrations of the compound. MTT cell viability assay shows that APPSwe 
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transfection of SH-SY5Y cells resulted in reduced cell viability, which was prevented 
when cells were pre-treated with agathisflavone (Figure 8B). This observation 
suggests that agathisflavone may be exerting a direct neuroprotective effect against 
amyloid beta in neuronal cells. 
Neuroprotective activity of agathisflavone is mediated through SIRT1 
Several mechanisms are known to mediate neuroinflammation and neurotoxicity as 
well as their prevention in both microglia and neurons. Emerging evidence suggests 
that the sirtuins, especially SIRT1 are linked to neuroprotection in both the microglia 
and neurons (Tang and Chua, 2008; Yeung et al., 2004). 
Having observed that agathisflavone produced neuroprotection through anti-
inflammatory effect in activated microglia, and through a direct action on neuronal 
cells, we were interested in determining whether the actions of the compound are 
attributable to possible increase in SIRT1 activity. Firstly, we investigated effects of 
agathisflavone on SIRT1 levels in BV2 microglia stimulated with LPS and observed 
that LPS stimulation resulted in significant (p<0.01) reduction in SIRT1 levels when 
compared to unstimulated cells (Figure 9A). On pre-treating cells with agathisflavone 
(5-20 µM) prior to LPS, there was a significant increase in the levels of SIRT1 
(Figure 9A). It is likely that enhancement of SIRT1 levels by agathisflavone 
contributes to anti-inflammatory activity (Yeung et al., 2004), and hence attenuation 
of neuroinflammation-induced neuronal damage. 
Similar results were obtained when SH-SY5Y neuronal cells were transfected with 
APPSwe plasmid. There was a marked reduction in SIRT1 levels resulting from Aβ 
effect (Figure 9B). When we treated cells with agathisflavone (5-20 µM) following 
exposure to APPSwe plasmid, we observed a significant (p<0.05) restoration in 
SIRT1 levels. Studies have shown that the expression of SIRT1 was significantly 
decreased while that of APP was increased in AD patients and in SK-N-SH cells 
treated with amyloid beta (Hou et al., 2016). This report is consistent with our 
findings showing lowered levels of SIRT1 following APPSwe transfection of SH-
SY5Y neuronal cells. Agathisflavone is therefore likely producing neuroprotection in 
neurons through epigenetic mechanisms similar to DNA methylation inhibitor 5-aza-
2′-deoxycytidine and the histone deacetylase inhibitor trichostatin A. 
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To confirm the role of SIRT1 in the neuroprotective effect of agathisflavone, we 
compared viability of SH-SY5Y exposed to conditioned medium from LPS-stimulated 
BV2 microglia treated with agathisflavone (20 µM) and medium from microglia 
treated with agathisflavone and SIRT1 inhibitor, EX527 (1 µM). In Figure 10A, 
exposure to conditioned medium shows a characteristic significant (p<0.01) 
reduction in cell viability, prevented when pre-treated with agathisflavone (20 µM). 
Neuroprotection by agathisflavone and against APPSwe transfection-induced 
neurotoxicity was significantly (p<0.01) reversed by EX527, suggesting that SIRT1 
contributes to the effects of agathisflavone in both LPS-stimulated BV2 microglia ans 
amyloid beta-induced neuronal death. 
Inhibition of NF-κB-mediated neuroinflammation by a stem bark extract of A. 
occidentale has been previously reported (Olajide et al., 2013) but this study shows 
that the leaf also contains bioactive compounds, one of which, agathisflavone, we 
have identified as being neuroprotective. This is the first report of its effects in 
APPSwe-induced neurotoxicity and, to our knowledge, the first evidence of the role 
played by SIRT1 in the anti-inflammatory and neuroprotective properties of a 
bioactive isolated from A. occidentale. 
Conclusions 
Taken together, our results suggest that agathisflavone inhibits neuroinflammation in 
BV2 microglia by targeting NF-κB signalling pathway. The compound also 
attenuated neuroinflammation- and amyloid beta –mediated neurotoxicity through 
mechanisms that are possibly linked to epigenetic mechanisms involving SIRT1 in 
the microglia and neurons. 
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Figure Legends 
Figure 1 
Structure of agathisflavone 
Figure 2 
Agathisflavone (5-20 µM) did not affect the viability of BV2 microglia stimulated with 
LPS (100 ng/ml) following incubation for 24 h. Cell viability was determined using 
MTT assay. 
Figure 3 
Pre-treatment with agathisflavone (5-20 µM) prior to stimulation with LPS (100 ng/ml) 
produced significant reduction in the secretion of pro-inflammatory cytokines TNFα 
(A), IL-6 (B) and IL-1β (C). Cytokine levels were determined in culture supernatants 
24 h after stimulation, using mouse ELISA kits for TNFα, IL-6 and IL-1β. All values 
are expressed as mean ± SEM for three independent experiments. Data were 
analysed using one-way ANOVA for multiple comparison with post-hoc Student 
Newman-Keuls test, *p<0.05, **p<0.01, ***p<0.001 in comparison with LPS control. 
Figure 4 
Agathisflavone reduced generation of cellular ROS in LPS-activated BV2 microglia. 
BV2 cells were treated with agathisflavone (5-10 µM) for 30 min prior to LPS 
stimulation for 24 h. ROS generation was measured in live cells by the fluorescence 
detection of dichlorofluorescein. All values are expressed as mean ± SEM for three 
independent experiments. Data were analysed using one-way ANOVA for multiple 
comparison with post-hoc Student Newman-Keuls test, **p<0.01, ***p<0.001 in 
comparison with LPS control. 
Figure 5 
Agathisflavone produced iNOS-mediated inhibition of NO production in LPS 
stimulated BV2 microglia. BV2 cells were treated with agathisflavone (5-20 µM) for 
30 min prior to LPS (100 ng/ml) stimulation for 24 h. (A) Culture supernatants were 
analysed for nitrite production using the Griess assay. (B) Cell lysates were analysed 
using immunoblotting for iNOS and actin. All values are expressed as mean ± SEM 
for three independent experiments. Data were analysed using one-way ANOVA for 
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multiple comparison with post-hoc Student Newman-Keuls test, *p<0.05, **p<0.01, 
***p<0.001 in comparison with LPS control. 
Figure 6 
Agathisflavone produced COX-2-mediated inhibition of PGE2 release in LPS 
stimulated BV2 microglia. BV2 cells were treated with agathisflavone (5-20 µM) for 
30 min prior to LPS (100 ng/ml) stimulation for 24 h. (A) Culture supernatants were 
analysed for PGE2 production using an enzyme immunoassay (EIA) for PGE2 (B) 
Cell lysates were analysed using immunoblotting for COX-2 and actin. All values are 
expressed as mean ± SEM for three independent experiments. Data were analysed 
using one-way ANOVA for multiple comparison with post-hoc Student Newman-
Keuls test, *p<0.05, ***p<0.001 in comparison with LPS control. 
Figure 7 
Inhibition of neuroinflammation by agathisflavone is mediated by targeting NF-κB 
signalling. (A) Agathisflavone (5-20 µM) supressed NF-κB luciferase activity in 
HEK273 cells transfected with pGL4.32 [luc2P/NF-κB RE/Hygro] vector and 
stimulated with TNFα (1 ng/ml) for 6 h. (B) BV2 cells were treated with 
agathisflavone (5-20 µM) for 30 min prior to LPS stimulation for 60 min. Cell lysates 
were analysed using immunoblotting for phospho- and total IκB. (C) Agathisflavone 
reduced phosphorylation of p65 sub-unit in LPS-activated BV2 microglia. BV2 cells 
were treated with agathisflavone (5-20 µM) prior to stimulation with LPS for 60 min. 
Cell lysates were analysed using immunoblotting for phospho-p65 and actin. (D) 
Agathisflavone prevented nuclear localisation of p65 subunit in LPS-stimulated BV2 
microglia. BV2 cells were treated with agathisflavone (5-20 µM) prior to LPS 
(100 ng/ml) for 60 min. Immunofluorescence experiments were carried out to detect 
p65 protein localisation using an anti-p65 antibody and Alexa Fluor 488-conjugated 
donkey anti-rabbit IgG antibody. Cells were counterstained with DAPI and 
fluorescence images acquired with an EVOS® FLoid® cell imaging station (scale 
bar: 100 µm). (E) Agathisflavone inhibited DNA binding of NF-κB in LPS-stimulated 
BV2 microglia. Nuclear extracts from cells were added to 96-well plates to which an 
oligonucleotide containing the NF-κB consensus site (5’-GGGACTTTCC-3’) has 
been immobilised, followed by addition of NF-κB and HRP-conjugated antibodies. 
Absorbance was read in a microplate reader. All quantitative experimental values are 
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expressed as mean ± SEM for three independent experiments. Data were analysed 
using one-way ANOVA for multiple comparison with post-hoc Student Newman-
Keuls test, *p<0.05, **p<0.01, ***p<0.001 in comparison with LPS control.  
ns: not significant  
Figure 8 
Agathisflavone is neuroprotective against neuroinflammation- and amyloid beta-
induced neuronal toxicity. (A) Cultured SH-SY5Y neurons were exposed to 
conditioned media from LPS (1 µg/ml)-stimulated BV2 microglia that have been pre-
treated with agathisflavone (5-20 µM). Neuronal viability was determined using MTT 
assay. (B) SH-SY5Y neurons were transfected with APPSwe plasmid and then 
treated with agathisflav ne (5-20 µM). Viability of the neurons was measured using 
MTT viability assay. All values are expressed as mean ± SEM for three independent 
experiments. Data were analysed using one-way ANOVA for multiple comparison 
with post-hoc Student Newman-Keuls test, *p<0.05, **p<0.01, ***p<0.001 in 
comparison with conditioned medium or APPSwe control. 
Figure 9 
Agathisflavone increases levels of SIRT1 in LPS-activated microglia and APPSwe-
transfected SH-SY5Y neurons. (A) BV2 microglia were stimulated with LPS 
(100 ng/ml) in the presence or absence of agathisflavone (5-20 µM) for 24 h. Levels 
of SIRT1 were then measured in nuclear extracts using mouse SIRT1 ELISA. (B) 
SH-SY5Y neuronal cells were transfected with APPSwe plasmid and then treated 
with agathisflavone (5-20 µM). Levels of SIRT1 were then measured in nuclear 
extracts using human SIRT1 ELISA. All values are expressed as mean ± SEM for 
three independent experiments. Data were analysed using one-way ANOVA for 
multiple comparison with post-hoc Student Newman-Keuls test, *p<0.05, **p<0.01, in 
comparison with LPS or APPSwe control. 
Figure 10 
Neuroprotection by agathislavone is reversed in the presence of SIRT1 inhibitor 
EX527 (1 µM). (A) Cultured SH-SY5Y neurons were exposed to conditioned media 
from LPS (1 µg/ml)-stimulated BV2 microglia that have been pre-treated with 
agathisflavone (20 µM) or EX527 (1 µM) + agathisflavone (20 µM). Neuronal viability 
was determined using MTT assay. (B) SH-SY5Y neurons were transfected with 
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APPSwe plasmid and then treated with agathisflavone (20 µM) or EX527 (1 µM) + 
agathisflavone (20 µM). Neuronal viability was determined using MTT assay. Viability 
of the neurons was measured using MTT viability assay. All values are expressed as 
mean ± SEM for three independent experiments. Data were analysed using one-way 
ANOVA for multiple comparison with post-hoc Student Newman-Keuls test, 
**p<0.01, in comparison with cells with no conditioned medium exposure, ***p<0.001 
in comparison with non-transfected cells, #p<0.05 in comparison with cells exposed 
to conditioned medium, ###p<0.001 in comparison with APPSwe transfected cells, 
&&p<0.01 agathisflavone (20 µM) treatment versus EX527 (1 µM) + agathisflavone 
(20 µM) treatment. 
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